CHICAGO, May 01, 2018 -- Lumere, a leading provider of data-driven analytics, evidence and expert guidance to help health systems reduce unwarranted clinical variation, today announced plans to collaborate with the Association of Healthcare Value Analysis Professionals’ (AHVAP) Industry Business Education Collaborative agreement.
This agreement includes educational offerings highlighting best-practice strategies and tactics to help health systems and value analysis professionals consistently apply evidence to clinical decisions. “Hospitals and clinicians are strapped to find the time and the resources to collect the vast amounts of available drug and device information and also to dissect and separate unbiased sources from biased ones,” said Lumere Chief Development Officer Gina Thomas, RN, MBA. “AHVAP is the perfect collaborator because of its dedication to applying a clinical and evidence-based perspective to the clinical decision process.”
According to AHVAP President Susan Knapp, RN, MS, CVAHP, the two organizations share a vision to improve patient value by reducing unnecessary clinical variation and reducing costs. “Variation in care is a major contributor to wasteful healthcare spending,” she said. “Our members have the potential to play important roles in curtailing that waste, and solutions like Lumere’s offer important resources for them and their facilities.”
According to Knapp, redefining and repositioning the role of value analysis offers an exceptional opportunity to bring about real change.
“Historically, value analysis leaders have had to react quickly to market place pressures. While that doesn’t change, integrating a clinical and evidence-based approach metric into all decisions will help advance the value analysis practice,” Knapp said.
Thomas, agrees with that assessment. “Our educational offerings will emphasize the fact that value analysis must be embedded within an organization’s clinical care governance as a patient-centered, multidisciplinary approach,” she said.
About Lumere
Lumere is at the forefront of clinical decision making for drugs and devices, offering evidence-based solutions and services for all providers that improve care and reduce cost across the patient journey. For more information, visit lumere.com, find us on LinkedIn, follow @LumereHQ on Twitter and like us on Facebook.
About AHVAP
The Association of Healthcare Value Analysis Professionals (AHVAP) is an organization of professionals whose expertise bridges the gap between clinical and supply chain process. Through the use of evidence, clinical and financial expertise value analysis facilitators play a pivotal role to ensure effective decision-making that positively impacts clinical, operational and financial outcomes. For more information, visit AHVAP.org, find us on LinkedIn, follow @AHVAP on Twitter and like us on Facebook.
Media Contact
Pam Flores
[email protected]
(773) 218-9260


Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9%
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight
Japan Earthquake Disrupts Auto and Chip Supply Chains
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation
World game at war: why some European nations have threatened a World Cup boycott
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring
Russia Charges Telegram Founder Pavel Durov With Facilitating Terrorism, Seeks International Arrest
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 



